Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer

This study has been terminated.
(Study early termination was due to slow recruitment and difficulties at achieving the required enrolment for the study.)
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: April 2, 2007
Last updated: August 7, 2014
Last verified: August 2014